Nicola Petrosillo

TL;DR: Compared with other epidemic coronaviruses, SARS-CoV-2 causes mild or asymptomatic disease in most cases; however, severe to critical illness occurs in a small proportion of infected individuals, with the highest rate seen in people older than 70 years.

TL;DR: COVID-19 seems not to be very different from SARS regarding its clinical features, however, it has a fatality rate lower than that of SARS and MERS and the possibility cannot be excluded that because of the less severe clinical picture of CO VID-19 it can spread in the community more easily than Mers and SARS.

TL;DR: The recommendations are presented in the form of 'basic' practices, recommended for all acute care facilities, and 'additional special approaches' to be considered when there is still clinical and/or epidemiological and molecular evidence of ongoing transmission, despite the application of the basic measures.

TL;DR: The results indicate that rifampicin should not be routinely combined with colistin in clinical practice, and that the increased rate of A. baumannii eradication with combination treatment could still imply a clinical benefit.

TL;DR: A high rate of resistance to colistin that is independently associated with worse outcome is observed in patients with CR-KP isolation in central Italy, with high morbidity and mortality.